Brief: Merck’S Remigromig, A Tri-Specific Agonist Of The Wingless-Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema
24/09/2026 11:46
BRIEF-Merck’S Remigromig, A Tri-Specific Agonist Of The Wingless-Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema Sept 24 (Reuters) - Merck & Co Inc MRK.N:
MERCK’S REMIGROMIG, A TRI-SPECIFIC AGONIST OF THE WINGLESS-RELATED INTEGRATION SITE (WNT) PATHWAY, MET PRIMARY ENDPOINT IN THE PIVOTAL PHASE 2B/3 BRUNELLO STUDY OF ADULTS WITH DIABETIC MACULAR EDEMA
MERCK & CO - REMIGROMIG DEMONSTRATES NON-INFERIORITY TO RANIBIZUMAB FOR BCVA AT WEEK 52
MERCK & CO - BOTH REMIGROMIG DOSES SHOW NON-INFERIORITY TO RANIBIZUMAB AT 52 WEEKS
MERCK & CO - HIGHER RATES OF PDR, VITREOUS HEMORRHAGE, AND DISCONTINUATIONS WITH REMIGROMIG
MERCK & CO INC: BOTH DOSES OF REMIGROMIG WERE GENERALLY WELL TOLERATED
Source text: ID:nBw2WnwBna
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsModerna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall (updated)
Brief: Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
Moderna falls as social media posts flag potential cancer vaccine data leak